Recent advances in antithrombotic treatment for acute coronary syndromes

References

• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607):349-60
   PubMed Web of Science ®Google Scholar
• Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313(22):1369-75
   PubMed Web of Science ®Google Scholar
• Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319(17):1105-11
   PubMed Web of Science ®Google Scholar
• Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther 2014;19(2):179-90
   PubMed Web of Science ®Google Scholar
• Berger PB, Bell MR, Grill DE, et al. Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). Am J Cardiol 1998;81(6):713-18
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98(16):1597-603
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339(23):1665-71
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98(20):2126-32
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102(6):624-9
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607-21
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376(9748):1233-43
   PubMed Web of Science ®Google Scholar
• Investigators C-O, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363(10):930-42
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80(5):486-501
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304(16):1821-30
   PubMed Web of Science ®Google Scholar
• Damani SB, Topol EJ. The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol 2010;56(2):109-11
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367(22):2100-9
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119(19):2553-60
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122(4):394-403
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Mylona P, et al. Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. J Thromb Thrombolysis 2011;32(3):328-33
   PubMed Web of Science ®Google Scholar
• Roe MT, Goodman SG, Ohman EM, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013;128(8):823-33
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118(16):1626-36
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). Am J Cardiol 2008;101(9):1364-6
   PubMed Web of Science ®Google Scholar
• Serebruany V. Prasugrel versus clopidogrel. N Engl J Med 2008;358(12):1298
   PubMedGoogle Scholar
• Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61(15):1601-6
   PubMed Web of Science ®Google Scholar
• British National Formulary. BNF March 2014. Secondary BNF March 2014 2014. Available from: www.medicinescomplete.com/mc/bnf/current/
   Google Scholar
• Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369(11):999-1010
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367(14):1297-309
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122(11):1056-67
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361(24):2330-41
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361(24):2318-29
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368(14):1303-13
   PubMed Web of Science ®Google Scholar
• Lange RA, Hillis LD. The duel between dual antiplatelet therapies. N Engl J Med 2013;368(14):1356-7
   PubMed Web of Science ®Google Scholar
• Ohlmann P, Reydel P, Jacquemin L, et al. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv 2012;5(1):69-76. S1
   PubMed Web of Science ®Google Scholar
• Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358(21):2205-17
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann FJ, et al. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295(13):1531-8
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33(20):2569-619
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57(19):e215-367
   PubMed Web of Science ®Google Scholar
• Chintala M, Strony J, Yang B, et al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2010;30(11):2143-9
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366(1):20-33
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 2012;380(9850):1317-24
   PubMed Web of Science ®Google Scholar
• US FDA. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee - ZONTIVITY (vorapaxar sulfate) 2.5mg Tablets. 2014
   Google Scholar
• O’Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011;123(17):1843-53
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy--I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6921):81-106
   PubMed Web of Science ®Google Scholar
• Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106(8):2710-15
   PubMed Web of Science ®Google Scholar
• Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012;344:e553
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355(9219):1936-42
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295(13):1519-30
   PubMed Web of Science ®Google Scholar
• Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005;111(11):1390-7
   PubMed Web of Science ®Google Scholar
• Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50(18):1742-51
   PubMed Web of Science ®Google Scholar
• Rao SV, Eikelboom JA, Granger CB, et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28(10):1193-204
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356(25):2653-5
   PubMed Web of Science ®Google Scholar
• Steg PG, van ’t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369(23):2207-17
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI). Secondary How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) 2012. Available from: http://clinicaltrials.gov/show/NCT01519518
   Google Scholar
• Shahzad A, Stables R. HEAT PPCI - How effective are antithrombotic therapies in PPCI American College of Cardiology 2014 Scientific Sessions. 2014
   Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355(21):2203-16
   PubMed Web of Science ®Google Scholar
• Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365(21):1980-9
   PubMed Web of Science ®Google Scholar
• Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J 2006;27(5):519-26
   PubMed Web of Science ®Google Scholar
• Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013;34(22):1670-80
   PubMed Web of Science ®Google Scholar
• Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362(9386):789-97
   PubMed Web of Science ®Google Scholar
• Committee AS, Investigators. Alexander JH, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877-85
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32(22):2781-9
   PubMed Web of Science ®Google Scholar
• Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011;32(20):2541-54
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9-19
   PubMed Web of Science ®Google Scholar
• Medscape Cardiology. Again, FDA Advisors Deliver Solid “No” to Rivaroxaban in ACS. Secondary Again, FDA Advisors Deliver Solid “No” to Rivaroxaban in ACS 2013. Available from: www.medscape.com/viewarticle/819318
   Google Scholar